سعر جيلينيا 0.5 مجم 28 كبسولة 2025

Gilenya (fingolimod) 0.5 mg hard capsules, pack of 28, by Novartis; sphingosine-1-phosphate receptor modulator for relapsing multiple sclerosis.

• Treatment of relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease) in patients 10 years of age and older.Population: 10 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (10% or more and more than placebo): headache, liver transaminase elevation, diarrhoea, cough, influenza, sinusitis, back pain, abdominal pain and pain in extremity.International label, same product · DailyMed (U.S. National Library of Medicine)

• Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalisation or class III/IV heart failure in the last 6 months.International label, same product · DailyMed (U.S. National Library of Medicine)
• History or presence of Mobitz type II second-degree or third-degree AV block or sick sinus syndrome, unless a functioning pacemaker is present.International label, same product · DailyMed (U.S. National Library of Medicine)
• Baseline QTc 500 msec or more, or arrhythmias needing class Ia or class III antiarrhythmics.International label, same product · DailyMed (U.S. National Library of Medicine)

• Bradyarrhythmia and AV block at treatment initiation; first-dose monitoring is required.International label, same product · DailyMed (U.S. National Library of Medicine)
• Increased risk of infections, including serious and fatal infections and progressive multifocal leukoencephalopathy (PML); review a recent CBC before starting.International label, same product · DailyMed (U.S. National Library of Medicine)
• Macular oedema: fundus examination near the start, at 3-4 months and with any visual change.International label, same product · DailyMed (U.S. National Library of Medicine)

• QT-prolonging drugs with a known risk of torsades de pointes (e.g. citalopram, chlorpromazine, haloperidol, methadone, erythromycin)Overnight continuous ECG monitoring in a medical facility at treatment initiation.DailyMed (U.S. National Library of Medicine)
• Systemic ketoconazoleRaises fingolimod and fingolimod-phosphate levels about 1.7-fold; monitor closely.DailyMed (U.S. National Library of Medicine)
• Live attenuated vaccinesAvoid during treatment and for 2 months after stopping; vaccine response may be reduced.DailyMed (U.S. National Library of Medicine)

• Pregnancy registry data suggest an increased prevalence of major birth defects compared with the general population; animal studies showed developmental toxicity. It takes about 2 months to eliminate fingolimod.International label, same product · DailyMed (U.S. National Library of Medicine)
• No human data; fingolimod is excreted in rat milk; weigh the benefits of breastfeeding against the mother's need for treatment and possible infant effects.International label, same product · DailyMed (U.S. National Library of Medicine)

• Fingolimod: Fingolimod is phosphorylated to fingolimod-phosphate, which binds S1P receptors and causes reversible sequestration of lymphocytes in lymphoid tissue, reducing peripheral lymphocyte counts (US GILENYA label).